索拉非尼治疗原发性肝癌的效果及对患者血清血管内皮生长因子受体2、胎盘生长因子水平的影响

廖维荣; 顾超; 张大伟

doi:10.3969/j.issn.1001-5256.2018.06.018

索拉非尼治疗原发性肝癌的效果及对患者血清血管内皮生长因子受体2、胎盘生长因子水平的影响

DOI: 10.3969/j.issn.1001-5256.2018.06.018

复旦大学附属金山医院普外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1473
- HTML全文浏览量: 17
- PDF下载量: 364
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-28
- 出版日期: 2018-06-20

Clinical efficacy of sorafenib in treatment of primary hepatic carcinoma and its effects on serum VEGFR-2 and PLGF levels

Department of General Surgery, Jinshan Hospital Affiliated to Fudan University

摘要

摘要: 目的探究索拉非尼治疗原发性肝癌（PHC）的临床效果及其对患者血清血管内皮生长因子受体（VEGFR）2和胎盘生长因子（PLGF）水平的影响。方法选取2014年7月-2016年3月在复旦大学附属金山医院接受治疗并确诊为PHC的患者110例,随机分为试验组和对照组,每组各55例。对照组给予常规治疗,试验组在常规治疗的基础上服用索拉非尼。采用ELISA检测2组患者血清VEGFR-2、PLGF水平,收集患者肝功能指标（AST、PT、TBil、Alb、ALT）。计量资料2组间比较采用独立样本t检验,组内干预前、后比较采用配对样本t检验;计数资料2组间比较采用χ2检验。结果试验组患者治疗后血清VEGFR-2、PLGF水平与治疗前相比均显著下降[（7053.2±1836.1）ng/L vs（8721.4±2427.8）ng/L,t=4.089,P<0.001;（468.4±136.5）pg/ml vs（656.8±191.4）pg/ml,t=5.975,P<0.001];试验组治疗后VEGFR-2、PLGF水平均显著低于对照组患者治疗后水平[（7053.2±1836.1）ng/L vs（8...
- 肝肿瘤 /
- 索拉非尼 /
- 血管内皮生长因子受体2 /
- 胎盘生长因子 /
- 治疗
Abstract: Objective To investigate the clinical efficacy of sorafenib in the treatment of primary hepatic carcinoma (PHC) and its effects on serum vascular endothelial growth factor receptor-2 (VEGFR-2) and placental growth factor (PLGF) levels. Methods A total of 110 patients with a confirmed diagnosis of PHC who received treatment in Jinshan Hospital Affiliated to Fudan University from July 2014 to March2016 were randomly and equally divided into observation group and control group. The control group was given routine treatment, while the observation group received sorafenib in addition to the routine treatment. Serum levels of VEGFR-2 and PLGF were measured by ELISA.Liver function parameters, aspartate aminotransferase (AST) , prothrombin time (PT) , total bilirubin (TBil) , albumin (Alb) , and alanine aminotransferase (ALT) , were also recorded. Comparison of continuous data between groups was made by independent samples t-test, and the changes in continuous data after intervention in each group were evaluated by paired samples t-test. Comparison of categorical data between groups was made by chi-square test. Results The observation group showed significant reductions in serum VEGFR-2 and PLGF levels after treatment (VEGFR-2: 7053. 2 ± 1836. 1 ng/L vs 8721. 4 ± 2427. 8 ng/L, t = 4. 089, P < 0. 001; PLGF: 468. 4 ± 136. 5 pg/ml vs 656. 8 ± 191. 4 pg/ml, t = 5. 975, P < 0. 001) . After treatment, the observation group had significantly lower serum VEGFR-2 and PLGF levels than the control group (VEGFR-2: 7053. 2 ± 1836. 1 ng/L vs 8097. 5 ± 2325. 4 ng/L, t = 2. 64, P < 0. 05; PLGF: 468. 4 ±136. 5 pg/ml vs 643. 3 ± 195. 8 pg/ml, t = 2. 48, P < 0. 05) . The observation group showed significant changes in serum AST and ALT levels after treatment (t = 4. 302 and 3. 097, both P < 0. 05) . After treatment, the observation group had significantly lower serum AST and ALT levels than the control group (t = 2. 56 and 2. 39, both P < 0. 05) . Compared with the control group, the observation group had better follow-up results, with a significantly increased disease control rate (27. 3% vs 47. 3%, χ2= 4. 705, P = 0. 030) , and had a significantly higher survival rate at 40 months after treatment (43. 6% vs 69. 1%, χ2= 7. 245, P = 0. 007) . Conclusion Sorafenib is effective in the treatment of PHC patients, as it can significantly reduce the serum levels of VEGFR-2 and PLGF, prolong the survival time of patients, and improve the prognosis of patients.
- liver neoplasms /
- sorafenib /
- vascular endothelial growth factor receptor-2 /
- placenta growth factor /
- therapy

HTML全文

参考文献(18)

[1]FATTOVICH G, STROFFOLINI T, ZAGNI I, et al.Hepatocellular carcinoma in cirrhosis:Incidence and risk factors[J].Gastroenterology, 2004, 127 (1) :35-50.

[2]YANG XF.Clinical effect of sorafenib on changes in TCM syndrome in patients with hepatocellular carcinoma[D].Lanzhou:Gansu Univ Tradit Chin Med, 2016. (in Chinese) 杨学芳.索拉非尼治疗肝细胞肝癌患者中医证候变化的临床观察[D].兰州:甘肃中医药大学, 2016.

[3]ZHANG XY, HUANG P, LI YJ, et al.Progress of therapies for the advanced hepatocellular carcinoma[J].J Mod Oncol, 2017, 25 (10) :1655-1659. (in Chinese) 张晓媛, 黄鹏, 李燕京, 等.晚期原发性肝癌治疗的研究进展[J].现代肿瘤医学, 2017, 25 (10) :1655-1659.

[4]LIU L.A prognostic evaluation of sorafenib combined with transarterial chemoembolization in treatment of unresectable hepatocellular carcinoma[D].Xi'an:Fourth Mil Med Univ, 2016. (in Chinese) 刘雷.索拉非尼联合TACE治疗不可切除肝细胞癌的预后评价系列研究[D].西安:第四军医大学, 2016.

[5]YU Q, CHEN ZA, CHEN P.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma[J].Chin J Clin Oncol Rehabil, 2016, 23 (5) :582-584. (in Chinese) 俞倩, 陈中安, 陈鹏.索拉菲尼治疗中晚期肝癌的临床疗效及安全性[J].中国肿瘤临床与康复, 2016, 23 (5) :582-584.

[6]National Health and Family Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[7]WATANABE H, OKADA M, KAJI Y, et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1) [J].Eur J Cancer, 2009, 45 (2) :228-247.

[8]SERGIO A, CRISTOFORI C, CARDIN R, et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) :The role of angiogenesis and invasiveness[J].Am J Gastroenterol, 2008, 103 (4) :914-921.

[9]ZHANG M, YE QF, ZHONG ZB, et al.Research progress of liver transplantation for primary hepatocellular carcinoma[J].Chin J Dig Surg, 2017, 16 (2) :215-220. (in Chinese) 张萌, 叶啟发, 钟自彪, 等.原发性肝癌肝移植的研究进展[J].中华消化外科杂志, 2017, 16 (2) :215-220.

[10]UESHIMA K, KUDO M.Molecular targeted agent for hepatocellular carcinoma[J].Nihon Rinsho, 2012, 70 (Suppl 8) :457-462.

[11]XIONG L, XU XM.Research progress of sorafenib combined with locoregional therapy in advanced hepatocellular carcinoma[J].China Med Herald, 2017, 14 (3) :42-45. (in Chinese) 熊琳, 徐细明.索拉非尼联合局部治疗在晚期肝癌中的研究进展[J].中国医药导报, 2017, 14 (3) :42-45.

[12]LIU XH, ZHAO YM, ZHAO XF, et al.Diagnostic and therapeutic progress on hepatocellular carcinoma[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :20-25. (in Chinese) 刘秀红, 赵一鸣, 赵晓飞, 等.肝细胞癌诊断与治疗研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :20-25.

[13]COPUR MS.Sorafenib in advanced hepatocellular carcinoma[J].New Engl J Med, 2008, 359 (23) :2498.

[14]ZHANG JK, WANG YY.Research advances in the pathogenesis and treatment of primary liver cancer[J].China Pharm, 2015, 26 (29) :4171-4173. (in Chinese) 张金坤, 王燕燕.原发性肝癌发生机制及其治疗的研究进展[J].中国药房, 2015, 26 (29) :4171-4173.

[15]XING TH, NIU HZ, ZHOU YY, et al.Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib:Initial experience in 23 cases[J].J Vasc Interv Radiol, 2014, 23 (5) :449-451. (in Chinese) 邢桃红, 牛焕章, 周媛媛, 等.TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志, 2014, 23 (5) :449-451.

[16]ZHOU XS, REN L, PENG L, et al.Efficacy of transcatheter arterial chemoembolization combined with sorafenib in treatment of patients with advanced hepatocellular carcinoma[J].J Prac Hepat, 2015, 18 (1) :59-62. (in Chinese) 周学士, 任雷, 彭蕾, 等.索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察[J].实用肝脏病杂志, 2015, 18 (1) :59-62.

[17]CHEN D, WANG KB, LI JZ, et al.Prediction of serum VEGFR-2 concentration on the short-term effects of TACE in patients with hepatocellular carcinoma[J].China Cancer, 2017, 26 (6) :476-481. (in Chinese) 陈丹, 王凯冰, 李加桩, 等.血清VEGFR-2浓度变化预测肝癌患者TACE近期疗效的研究[J].中国肿瘤, 2017, 26 (6) :476-481.

[18]ZHENG JP, SHAO GL, LUO J, et al.Sorafenib for the treatment of intermediate-advanced hepatocellular carcinomas:its safety and prognostic factors[J].J Vasc Interv Radiol, 2014, 23 (3) :222-225. (in Chinese) 郑家平, 邵国良, 罗君, 等.索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J].介入放射学杂志, 2014, 23 (3) :222-225.

施引文献

资源附件(0)

访问统计